FibroGen Gets 1 Anemia Patent Revived On Appeal

By Bonnie Eslinger (August 24, 2021, 3:56 PM BST) -- A London appellate court handed FibroGen a partial win on Tuesday, reviving one of its anemia treatment patents and saying that its rival Akebia's planned treatment connected to kidney disease would infringe it.

The Court of Appeal has handed pharma company FibroGen a partial victory against rival Akebia in a patent battle over an anemia treatment. (iStock) But the Court of Appeal dismissed the biopharmaceutical company's appeal on three other patents related to anemia associated with other chronic diseases, backing a decision by the lower court that they were obvious advances based on earlier life-science work. The court found that the patents were sufficiently...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!